Crizotinib is indicated for the treatment of advanced non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an accurate and validated assay.
Crizotinib is indicated for the treatment of advanced NSCLC that is ROS1-positive as detected by an accurate and validated assay.
Sign Out